fluorouracil has been researched along with Anorexia in 73 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Anorexia: The lack or loss of APPETITE accompanied by an aversion to food and the inability to eat. It is the defining characteristic of the disorder ANOREXIA NERVOSA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX." | 9.16 | An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. ( Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z, 2012) |
| "A phase-I clinical study of a combination therapy of vinorelbine and capecitabine was conducted in anthracycline- and taxane-pretreated patients with advanced/recurrent breast cancer." | 9.12 | [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ( Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 9.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 9.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 9.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 9.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 7.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 7.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| " From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer." | 6.66 | [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986) |
| "The purpose of this phase II study was to explore the efficacy and safety of an alternating regimen consisting of folinic acid, 5-fluorouracil (5-FU) and oxaliplatin (mFOLFOX6) plus bevacizumab, and folinic acid, 5-FU and irinotecan (FOLFIRI) plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer." | 5.22 | Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801). ( Akagi, Y; Emi, Y; Higashi, H; Ishikawa, H; Kusumoto, T; Maehara, Y; Matsuda, H; Miwa, K; Ogata, Y; Oki, E; Saeki, H; Samura, H; Sueyoshi, S; Tanaka, T; Tokunaga, S; Touyama, T, 2016) |
| "Oral administration of cyclophosphamide (CTX) and capecitabine may have a greater potential for treatment of metastatic breast cancer (MBC) due to anti-angiogenesis resulting from the metronomic dosage and upregulation of thymidine phosphorylase by CTX." | 5.16 | An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study. ( Hong, X; Hu, X; Leaw, S; Lu, J; Shao, Z; Wang, J; Wang, Z, 2012) |
| "A phase-I clinical study of a combination therapy of vinorelbine and capecitabine was conducted in anthracycline- and taxane-pretreated patients with advanced/recurrent breast cancer." | 5.12 | [A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer]. ( Aogi, K; Fujii, H; Hatake, K; Noguchi, S; Saeki, T; Sano, M; Tabei, T; Tokuda, Y, 2006) |
| "We performed a controlled study to compare the response to cyclophosphamide (CPA), adriamycin (ADM), and fluorouracil (5-FU) (CAF therapy) with that to uracil-tegafur (UFT) plus tamoxifen (TAM) (UFT+TAM therapy), when given as postoperative adjuvant therapy to women with breast cancer." | 5.12 | [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set ( Inaji, H; Koyama, H; Mori, T; Nakao, K; Oka, T; Oshima, A; Ozawa, K; Saito, Y; Sakai, K; Senoo, T; Taguchi, T; Terasawa, T, 2006) |
| "A multicentral cooperative study was conducted to evaluate the clinical efficacy and toxicity of l-Leucovorin (l-LV) and 5-fluorouracil (5-FU) in advanced colorectal cancer." | 5.08 | [A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)]. ( Abe, T; Kikkawa, N; Konishi, K; Maehara, Y; Ota, J; Sowa, M; Taguchi, T; Takashima, S; Yabushita, K; Yasutomi, M, 1995) |
| "The direct effect and safety of carmofur (Mifurol) in cases of advanced and recurrent breast cancer were evaluated as a cooperative study at twenty-two facilities nationwide." | 5.08 | [Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer]. ( Abe, R; Enomoto, K; Koyama, H; Kusama, M; Nishi, T; Sonoo, H; Takashima, S; Tominaga, T; Yamaguchi, S; Yoshida, M, 1995) |
| "We undertook a randomized trial in patients with advanced colorectal cancer, comparing 5-fluorouracil and leucovorin versus combination of these agents with additional cisplatin." | 5.08 | [Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation]. ( Katsumata, K; Ohno, M; Shibata, K; Yamamoto, K; Yamashita, S, 1996) |
| "Thirty patients with a diagnosis of metastatic adenocarcinoma of the lung were entered on a trial to evaluate the antitumor efficacy of 5-fluorouracil 370 mg/m2 daily for 5 days every four weeks in combination with folinic acid 200 mg/m2, 60 min prior to 5FU." | 5.06 | 5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung. ( Aitken, SE; Evans, WK; Ezzat, A; Maroun, JA; Rusthoven, J; Shepherd, FA; Stewart, DJ; Wierzbicki, R, 1990) |
| "Gemcitabine plus cisplatin (GP) is a standard chemotherapy option for patients with advanced biliary tract cancer (BTC)." | 3.79 | Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study. ( Han, SS; Hong, EK; Kim, DH; Kim, JH; Kim, TH; Koh, YH; Lee, JH; Lee, WJ; Park, SJ; Woo, SM, 2013) |
| "Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival." | 3.77 | Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia. ( Doi, T; Fuse, N; Ikeda, E; Kaneko, K; Kojima, T; Minashi, K; Nihei, K; Ohtsu, A; Onozawa, M; Tahara, M; Yano, T; Yoshino, T, 2011) |
| "Combination three-drug chemotherapy with adriamycin (ADM), cyclophosphamide (CPM), and 5-fluorouracil (5-FU) was performed in 24 cases of advanced bladder cancer who underwent surgical treatment, and three cases with recurrent or metastatic bladder cancer." | 3.66 | Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil. ( Machida, T; Masuda, F; Ohishi, Y; Tashiro, K, 1983) |
| "Twenty-one Japanese colorectal cancer patients received intravenous FOLFIRI (bolus irinotecan, folinic acid, and fluorouracil followed by 46-hour fluorouracil infusion) followed by bevacizumab (5 mg/kg) in Cycle 1." | 2.79 | Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms. ( Doi, T; Fuse, N; Hamamoto, Y; Hatake, K; Iwasaki, J; Matsumoto, H; Mizunuma, N; Motomura, S; Ohtsu, A; Suenaga, M; Yamaguchi, T; Yamanaka, Y, 2014) |
| "5-fluorouracil continuous infusion for gastric cancer with peritoneal metastasis." | 2.78 | Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). ( Boku, N; Denda, T; Doi, T; Fukuda, H; Goto, M; Hamamoto, Y; Nasu, J; Ohtsu, A; Shirao, K; Takashima, A; Yamada, Y; Yamaguchi, K, 2013) |
| "Patients with advanced or recurrent gastric cancer were randomly assigned to an experimental arm or a control arm." | 2.78 | A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer. ( Ba, Y; Deng, T; Guo, Z; Hu, C; Huang, D; Meng, J; Wan, H; Wang, M; Xiong, J; Xu, N; Yan, Z; Yao, Y; Yu, Z; Zhang, Y; Zheng, R; Zhuang, Z, 2013) |
| "To evaluate the activity and tolerance of gemcitabine in combination with docetaxel and capecitabine in previously untreated patients with advanced pancreatic cancer." | 2.77 | Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study. ( Amarantidis, K; Chamalidou, E; Chelis, L; Chiotis, A; Courcoutsakis, N; Dimopoulos, P; Kakolyris, S; Prassopoulos, P; Tentes, A; Xenidis, N, 2012) |
| "Fresh patients with squamous cell carcinoma of the head and neck were enrolled in the study." | 2.73 | [Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck]. ( Iwabuchi, H; Nakayama, S; Uchiyama, K, 2007) |
| " Results from phase I determined the recommended dosage to be examined in phase II for effect on survival period, clinical benefit response (CBR), tumor response and safety." | 2.72 | A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer. ( Funakoshi, A; Furuse, J; Ishii, H; Okusaka, T; Sumii, T; Ueno, H, 2006) |
| "Capecitabine (Xeloda) is a novel, oral, selectively tumor-activated fluoropyrimidine with proven activity in the treatment of advanced colorectal cancer." | 2.71 | A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer. ( Cho, JY; Choi, SH; Chung, HC; Han, JY; Hong, YS; Kang, JH; Lee, KS; Lee, SI; Noh, SH; Park, JN; Song, SY, 2004) |
| " Schedule 1 maximum tolerated dose of gemcitabine was 600 mg/m(2)/week when combined with 5-fluorouracil (5-FU) at 200 mg/m(2)/day (Days 1-21) repeated every 4 weeks." | 2.70 | Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. ( Bertucci, D; Mani, S; Ratain, MJ; Schilsky, RL; Stadler, WM; Vogelzang, NJ, 2001) |
| "For patients with unresectable gastric cancer registered between July 1994 and September 1995, the following dosage regimen was examined: a drip infusion of cisplatin (CDDP) at 7 mg/m2/day for 5 consecutive days and 2-day withdrawal a week for 3 weeks with concomitant sustained drip infusion of 5-FU at 300 mg/m2/day for 21 days." | 2.69 | [A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group]. ( Ishida, T; Iwanaga, T; Katsu, K; Kobayashi, K; Narahara, H; Okajima, K; Okuno, M; Otani, T; Sowa, M; Taguchi, T; Takami, M; Yamamoto, H; Yasutake, K; Yasutomi, M, 1998) |
| "Forty-eight patients with unresectable gastric cancer were enrolled for a randomized trial of FP (n = 24) vs FEP (n = 24) combination chemotherapy with respect to their effects on survival period." | 2.68 | [Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy]. ( Horiuchi, Y; Ina, K; Iwase, H; Kaneko, H; Kuroiwa, A; Kusugami, K; Morise, K; Oka, Y; Shinoda, M; Suga, S, 1995) |
| "Leukocytopenia was more severe in group B." | 2.67 | [Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy] ( Ito, T; Komatsu, Y; Moriya, N; Ogasawara, H; Saito, S; Sakata, Y; Sugimoto, N; Tamura, Y; Tsushima, K; Yamada, Y, 1994) |
| "or t." | 2.66 | [Phase II study of 5-FU tablet in bladder tumor]. ( Fukuoka, H; Fukushima, S; Furuhata, A; Ishizuka, E; Kondo, I; Kubota, Y; Moriyama, M; Nagamoto, A; Satomi, Y; Shuin, T, 1989) |
| " From the above results, THP in combination with cyclophosphamide and 5-Fluorouracil is comparable to ADR in efficacy and can be regarded as having better safety than ADR for the treatment of breast cancer." | 2.66 | [A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer]. ( Abe, O; Abe, R; Enomoto, K; Fujimoto, M; Iino, Y; Koyama, H; Nomura, Y; Tanaka, T; Tominaga, T, 1986) |
| "Chemotherapy for colorectal cancer is now improving rapidly due to new drugs like oxaliplatin and molecular targeting drugs." | 2.43 | [S-1 as a single agent for colorectal cancer]. ( Eguchi, T; Shirao, K, 2006) |
| "Even in advanced penile squamous cell carcinoma with nodal invasion, a response rate of 60% could be achieved." | 1.40 | Intraarterial chemotherapy as the first-line therapy in penile cancer. ( Chen, CH; Chiang, PH; Shen, YC, 2014) |
| "Hyporexia/anorexia is a relevant clinical problem affecting the quality of life of many cancer patients." | 1.37 | Steroids, cancer and vertebral fractures: a dreaded combination. ( Uña Cidón, E, 2011) |
| " In May 2002, we devised a new regimen by intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells, and thirteen patients with advanced colorectal cancer (Stage IV) were treated with this regimen." | 1.34 | [The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| "19 out of 29 patients were colon cancer, and the other 10 were rectal cancer." | 1.34 | [Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer]. ( Honda, K; Kondo, H; Ohura, K; Sumiyoshi, T; Takahari, D; Tanaka, S; Tsuji, Y; Tsushima, T; Yoshizaki, N, 2007) |
| "Ten patients with advanced pancreatic cancer (4 in Stage IVa and 6 in Stage IVb) were treated with this new regimen." | 1.34 | [The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer]. ( Hirata, K; Hiyama, S; Inui, N; Kimura, H; Kimura, Y; Koito, K; Shirasaka, T; Yamada, Y; Yamamitsu, S, 2007) |
| " We designed a new regimen to evaluate the efficacy and feasibility of weekly low dose CPT-11 combined with 5-FU/l-LV therapy based on an RPMI regimen against advanced and recurrent colorectal cancer." | 1.33 | [Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study]. ( Deguchi, Y; Kaneko, I; Kii, E; Murata, T; Sonoda, K; Tsubono, M; Yasuda, K, 2006) |
| "Most nonendocrine pancreatic neoplasms are adenocarcinomas of ductal cell or acinar origin." | 1.31 | Squamous cell carcinoma of the pancreas with cystic degeneration. ( Colarian, J; Fowler, D; Poolos, S; Schor, J, 2000) |
| "Phase 2 study of 5'-DFUR in bladder and prostatic cancer was conducted at 15 collaborative institutions including Okayama University." | 1.28 | [Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer]. ( Akebi, N; Josen, T; Kobashi, K; Matsumura, Y; Nanba, K; Nasu, Y; Ochi, J; Ohmori, H; Saika, T; Tanahashi, T, 1991) |
| "Fifty-two non-resectable and recurrent cancer patients with prior treatment, were entered in this study; 1 esophageal, 33 gastric, 1 duodenal, 4 colorectal, 2 pancreatic, 2 bile duct, and 9 breast cancer." | 1.28 | [Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients]. ( Hattori, T; Jinushi, K; Kim, R; Niimoto, M; Saeki, K; Saeki, T; Toi, M; Yanagawa, E; Yoshinaka, K, 1989) |
| "Thyroid cancer, nasal cancer and paranasal sinus cancer gave the best results." | 1.27 | [Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture]. ( Hattori, Y; Horiuchi, M; Miyake, H; Murakami, T; Otake, H; Sawaki, S; Takahashi, H; Takeyama, I; Tamamushi, N; Yao, K, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (12.33) | 18.7374 |
| 1990's | 15 (20.55) | 18.2507 |
| 2000's | 27 (36.99) | 29.6817 |
| 2010's | 20 (27.40) | 24.3611 |
| 2020's | 2 (2.74) | 2.80 |
| Authors | Studies |
|---|---|
| Kobayashi, N | 1 |
| Omae, K | 1 |
| Horita, Y | 1 |
| Ueno, H | 2 |
| Mizuno, N | 1 |
| Uesugi, K | 1 |
| Sudo, K | 1 |
| Ozaka, M | 1 |
| Hayashi, H | 1 |
| Okano, N | 1 |
| Kamei, K | 1 |
| Yamaguchi, A | 1 |
| Kobayashi, S | 1 |
| Suzuki, S | 2 |
| Ishihara, S | 1 |
| Uchiyama, T | 1 |
| Todaka, A | 1 |
| Fukutomi, A | 1 |
| Arima, S | 1 |
| Kawahira, M | 1 |
| Shimokawa, M | 2 |
| Ido, A | 1 |
| Koga, F | 1 |
| Ueda, Y | 1 |
| Nakazawa, J | 1 |
| Komori, A | 1 |
| Otsu, S | 1 |
| Fukahori, M | 1 |
| Makiyama, A | 1 |
| Taguchi, H | 1 |
| Honda, T | 1 |
| Shibuki, T | 1 |
| Mitsugi, K | 1 |
| Nio, K | 1 |
| Ide, Y | 1 |
| Ureshino, N | 1 |
| Mizuta, T | 1 |
| Shirakawa, T | 1 |
| Otsuka, T | 1 |
| Shiomi, Y | 1 |
| Ohira, Y | 1 |
| Yoshimura, M | 1 |
| Ozaki, T | 1 |
| Takei, M | 1 |
| Tanaka, T | 4 |
| Kato, K | 2 |
| Nakajima, TE | 1 |
| Ito, Y | 1 |
| Katada, C | 1 |
| Ishiyama, H | 1 |
| Tokunaga, SY | 1 |
| Tanaka, M | 2 |
| Hironaka, S | 2 |
| Hashimoto, T | 1 |
| Ura, T | 2 |
| Kodaira, T | 1 |
| Yoshimura, K | 1 |
| Huang, D | 1 |
| Ba, Y | 1 |
| Xiong, J | 1 |
| Xu, N | 1 |
| Yan, Z | 1 |
| Zhuang, Z | 1 |
| Yu, Z | 2 |
| Wan, H | 1 |
| Zhang, Y | 1 |
| Deng, T | 1 |
| Zheng, R | 1 |
| Guo, Z | 1 |
| Hu, C | 1 |
| Wang, M | 1 |
| Yao, Y | 1 |
| Meng, J | 1 |
| Shirao, K | 3 |
| Boku, N | 4 |
| Yamada, Y | 5 |
| Yamaguchi, K | 3 |
| Doi, T | 5 |
| Goto, M | 1 |
| Nasu, J | 1 |
| Denda, T | 1 |
| Hamamoto, Y | 4 |
| Takashima, A | 1 |
| Fukuda, H | 1 |
| Ohtsu, A | 4 |
| Ueda, S | 1 |
| Yasui, H | 1 |
| Nishina, T | 1 |
| Tsuda, M | 1 |
| Tsumura, T | 1 |
| Sugimoto, N | 2 |
| Shimodaira, H | 1 |
| Tokunaga, S | 2 |
| Moriwaki, T | 1 |
| Esaki, T | 1 |
| Nagase, M | 1 |
| Fujitani, K | 1 |
| Morita, S | 1 |
| Okamoto, I | 1 |
| Hyodo, I | 1 |
| Likhacheva, A | 1 |
| Jhingran, A | 1 |
| Bodurka, DC | 1 |
| Sun, C | 1 |
| Sam, M | 1 |
| Eifel, PJ | 1 |
| Woo, SM | 1 |
| Lee, WJ | 1 |
| Kim, JH | 1 |
| Kim, DH | 1 |
| Han, SS | 1 |
| Park, SJ | 1 |
| Kim, TH | 1 |
| Lee, JH | 1 |
| Koh, YH | 1 |
| Hong, EK | 1 |
| Suenaga, M | 1 |
| Fuse, N | 2 |
| Yamaguchi, T | 2 |
| Yamanaka, Y | 1 |
| Motomura, S | 1 |
| Matsumoto, H | 1 |
| Mizunuma, N | 2 |
| Hatake, K | 2 |
| Iwasaki, J | 1 |
| Chiang, PH | 1 |
| Chen, CH | 1 |
| Shen, YC | 1 |
| Miwa, K | 1 |
| Oki, E | 2 |
| Emi, Y | 2 |
| Saeki, H | 2 |
| Kusumoto, T | 2 |
| Akagi, Y | 2 |
| Ogata, Y | 2 |
| Samura, H | 1 |
| Ishikawa, H | 1 |
| Sueyoshi, S | 1 |
| Higashi, H | 1 |
| Matsuda, H | 1 |
| Touyama, T | 2 |
| Maehara, Y | 3 |
| Sadanaga, N | 1 |
| Kimura, M | 1 |
| Baba, H | 1 |
| Shirouzu, K | 1 |
| Tebbutt, NC | 1 |
| Price, TJ | 1 |
| Ferraro, DA | 1 |
| Wong, N | 1 |
| Veillard, AS | 1 |
| Hall, M | 1 |
| Sjoquist, KM | 1 |
| Pavlakis, N | 1 |
| Strickland, A | 1 |
| Varma, SC | 1 |
| Cooray, P | 1 |
| Young, R | 1 |
| Underhill, C | 1 |
| Shannon, JA | 1 |
| Ganju, V | 1 |
| Gebski, V | 1 |
| Perboni, S | 1 |
| Bowers, C | 1 |
| Kojima, S | 1 |
| Asakawa, A | 1 |
| Inui, A | 1 |
| Uña Cidón, E | 1 |
| Komatsu, Y | 2 |
| Muro, K | 2 |
| Sato, A | 2 |
| Koizumi, W | 1 |
| Takiuchi, H | 1 |
| Ferrucci, LM | 1 |
| Bell, D | 1 |
| Thornton, J | 1 |
| Black, G | 1 |
| McCorkle, R | 1 |
| Heimburger, DC | 1 |
| Saif, MW | 1 |
| Hara, T | 1 |
| Nishikawa, K | 1 |
| Sakatoku, M | 1 |
| Oba, K | 1 |
| Sakamoto, J | 1 |
| Omura, K | 1 |
| Ikeda, E | 1 |
| Kojima, T | 1 |
| Kaneko, K | 1 |
| Minashi, K | 1 |
| Onozawa, M | 1 |
| Nihei, K | 1 |
| Yano, T | 2 |
| Yoshino, T | 1 |
| Tahara, M | 1 |
| Xenidis, N | 1 |
| Chelis, L | 1 |
| Amarantidis, K | 1 |
| Chamalidou, E | 1 |
| Dimopoulos, P | 1 |
| Courcoutsakis, N | 1 |
| Tentes, A | 1 |
| Chiotis, A | 1 |
| Prassopoulos, P | 1 |
| Kakolyris, S | 1 |
| Wang, Z | 1 |
| Lu, J | 1 |
| Leaw, S | 1 |
| Hong, X | 1 |
| Wang, J | 1 |
| Shao, Z | 1 |
| Hu, X | 1 |
| Chakravarty, T | 1 |
| Crane, CH | 1 |
| Ajani, JA | 1 |
| Mansfield, PF | 1 |
| Briere, TM | 1 |
| Beddar, AS | 1 |
| Mok, H | 1 |
| Reed, VK | 1 |
| Krishnan, S | 1 |
| Delclos, ME | 1 |
| Das, P | 1 |
| Takahashi, K | 1 |
| Mori, T | 2 |
| Ohue, M | 1 |
| Yamada, R | 1 |
| Yamamoto, Y | 1 |
| Morinaga, S | 1 |
| Noguchi, Y | 1 |
| Yoshida, S | 1 |
| Matsumoto, A | 1 |
| Maruyama, S | 2 |
| Ando, M | 1 |
| Watayo, T | 1 |
| Kondo, Y | 1 |
| Terashima, M | 1 |
| Taguchi, T | 4 |
| Hong, YS | 1 |
| Song, SY | 1 |
| Lee, SI | 1 |
| Chung, HC | 1 |
| Choi, SH | 1 |
| Noh, SH | 1 |
| Park, JN | 1 |
| Han, JY | 1 |
| Kang, JH | 1 |
| Lee, KS | 1 |
| Cho, JY | 1 |
| Nakashima, T | 1 |
| Kuratomi, Y | 1 |
| Yamamoto, T | 1 |
| Masuda, M | 1 |
| Hirakawa, N | 1 |
| Nakamura, K | 1 |
| Shioyama, Y | 1 |
| Umezaki, T | 1 |
| Komune, S | 1 |
| Sadahiro, S | 1 |
| Mitomi, T | 1 |
| Noto, T | 1 |
| Kumada, K | 1 |
| Hiki, Y | 1 |
| Yamakawa, T | 1 |
| Amano, T | 1 |
| Oki, S | 1 |
| Otani, Y | 1 |
| Oka, H | 1 |
| Takahashi, T | 1 |
| Takemiya, S | 1 |
| Nishiyama, K | 1 |
| Yamamura, T | 1 |
| Tsuchiya, S | 1 |
| Ogawa, N | 1 |
| Harada, N | 1 |
| Takeo, Y | 1 |
| Tanaka, S | 2 |
| Hayashi, T | 1 |
| Suzuki, M | 1 |
| Hanyu, F | 1 |
| Takahari, D | 2 |
| Tsuji, Y | 2 |
| Sagawa, T | 1 |
| Honda, K | 2 |
| Sumiyoshi, T | 2 |
| Yoshizaki, N | 2 |
| Kuroiwa, G | 1 |
| Kondo, H | 2 |
| Miyata, Y | 1 |
| Shimada, Y | 1 |
| Muto, M | 1 |
| Hamaguchi, T | 1 |
| Mera, K | 1 |
| Tanigawara, Y | 1 |
| Ueda, M | 1 |
| Endo, I | 1 |
| Fujii, Y | 1 |
| Miura, Y | 1 |
| Kubota, T | 1 |
| Tanaka, K | 1 |
| Ichikawa, Y | 1 |
| Togo, S | 1 |
| Shimada, H | 1 |
| Okusaka, T | 1 |
| Ishii, H | 1 |
| Funakoshi, A | 1 |
| Furuse, J | 1 |
| Sumii, T | 1 |
| Eguchi, T | 1 |
| Sano, M | 1 |
| Tokuda, Y | 1 |
| Noguchi, S | 1 |
| Aogi, K | 1 |
| Saeki, T | 2 |
| Tabei, T | 1 |
| Fujii, H | 1 |
| Tsubono, M | 1 |
| Kaneko, I | 1 |
| Kii, E | 1 |
| Murata, T | 1 |
| Deguchi, Y | 1 |
| Sonoda, K | 1 |
| Yasuda, K | 1 |
| Inaji, H | 1 |
| Sakai, K | 1 |
| Oka, T | 1 |
| Ozawa, K | 1 |
| Saito, Y | 1 |
| Senoo, T | 1 |
| Terasawa, T | 1 |
| Nakao, K | 1 |
| Koyama, H | 3 |
| Oshima, A | 1 |
| Yamamoto, K | 2 |
| Nakai, M | 1 |
| Nohara, K | 1 |
| Yamatodani, A | 1 |
| Shitara, K | 1 |
| Munakata, M | 1 |
| Kudo, T | 1 |
| Kasai, M | 1 |
| Muto, O | 1 |
| Okada, R | 1 |
| Mitobe, S | 1 |
| Ishiguro, A | 1 |
| Sakuraba, H | 1 |
| Ikami, I | 1 |
| Sakata, Y | 2 |
| Uchiyama, K | 1 |
| Iwabuchi, H | 1 |
| Nakayama, S | 1 |
| Tsushima, T | 1 |
| Ohura, K | 1 |
| Minami, K | 1 |
| Kameda, A | 1 |
| Tsutani, Y | 1 |
| Suzuki, T | 1 |
| Miyahara, E | 1 |
| Noso, Y | 1 |
| Yamamitsu, S | 2 |
| Kimura, H | 2 |
| Inui, N | 2 |
| Hiyama, S | 2 |
| Hirata, K | 2 |
| Kimura, Y | 2 |
| Koito, K | 1 |
| Shirasaka, T | 3 |
| Tashiro, K | 1 |
| Machida, T | 1 |
| Masuda, F | 1 |
| Ohishi, Y | 1 |
| McCracken, JD | 1 |
| Ray, P | 1 |
| Heilbrun, LK | 1 |
| Vaitkevicius, VK | 1 |
| Saiki, JH | 1 |
| Rivkin, SE | 1 |
| Rossof, AH | 1 |
| Moore, TN | 1 |
| Konishi, K | 2 |
| Yabushita, K | 2 |
| Ota, J | 1 |
| Takashima, S | 2 |
| Abe, T | 1 |
| Kikkawa, N | 1 |
| Yasutomi, M | 2 |
| Sowa, M | 2 |
| Takada, O | 1 |
| Kawamura, T | 1 |
| Hasebe, K | 1 |
| Tsugawa, K | 1 |
| Maeda, K | 1 |
| Kuroda, Y | 1 |
| Tsuji, M | 1 |
| Demachi, H | 1 |
| Kusama, M | 1 |
| Tominaga, T | 3 |
| Enomoto, K | 2 |
| Yoshida, M | 1 |
| Sonoo, H | 1 |
| Abe, R | 2 |
| Nishi, T | 1 |
| Yamaguchi, S | 1 |
| Shinoda, M | 1 |
| Morise, K | 1 |
| Kusugami, K | 1 |
| Iwase, H | 1 |
| Ina, K | 1 |
| Kaneko, H | 1 |
| Horiuchi, Y | 1 |
| Kuroiwa, A | 1 |
| Suga, S | 1 |
| Oka, Y | 1 |
| Tsushima, K | 1 |
| Saito, S | 1 |
| Ito, T | 1 |
| Ogasawara, H | 1 |
| Tamura, Y | 1 |
| Moriya, N | 1 |
| Katsumata, K | 1 |
| Ohno, M | 1 |
| Shibata, K | 1 |
| Yamashita, S | 1 |
| Ando, E | 1 |
| Yamashita, F | 1 |
| Tanikawa, K | 1 |
| Okabo, S | 1 |
| Arai, T | 1 |
| Lee, M | 1 |
| Murase, N | 1 |
| Tsubaki, M | 1 |
| Endo, M | 1 |
| Wada, Y | 1 |
| Shimoju, K | 1 |
| Sakurazawa, K | 1 |
| Sugihara, K | 1 |
| Maruyama, M | 1 |
| Yabata, E | 1 |
| Kawasaki, T | 1 |
| Sasaki, T | 1 |
| Fujii, K | 1 |
| Nakashima, K | 1 |
| Ohno, T | 1 |
| Anai, H | 1 |
| Shimamoto, Y | 1 |
| Kato, T | 1 |
| Fukushima, M | 1 |
| Narahara, H | 1 |
| Otani, T | 1 |
| Iwanaga, T | 1 |
| Okajima, K | 1 |
| Katsu, K | 1 |
| Kobayashi, K | 1 |
| Okuno, M | 1 |
| Takami, M | 1 |
| Ishida, T | 1 |
| Yasutake, K | 1 |
| Yamamoto, H | 1 |
| Chen, JS | 1 |
| Jan, YY | 1 |
| Lin, YC | 1 |
| Wang, HM | 1 |
| Chang, WC | 1 |
| Liau, CT | 1 |
| Minamide, J | 1 |
| Aoyama, N | 1 |
| Koizumi, H | 1 |
| Yoneyama, K | 1 |
| Hoshino, S | 1 |
| Kamiya, J | 1 |
| Tamai, S | 1 |
| Kameda, Y | 1 |
| Colarian, J | 1 |
| Fowler, D | 1 |
| Schor, J | 1 |
| Poolos, S | 1 |
| Olencki, T | 1 |
| Peereboom, D | 1 |
| Wood, L | 1 |
| Budd, GT | 1 |
| Novick, A | 1 |
| Finke, J | 1 |
| McLain, D | 1 |
| Elson, P | 1 |
| Bukowski, RM | 1 |
| Mani, S | 1 |
| Vogelzang, NJ | 1 |
| Bertucci, D | 1 |
| Stadler, WM | 1 |
| Schilsky, RL | 1 |
| Ratain, MJ | 1 |
| Ohmori, H | 1 |
| Matsumura, Y | 1 |
| Ochi, J | 1 |
| Kobashi, K | 1 |
| Akebi, N | 1 |
| Saika, T | 1 |
| Nanba, K | 1 |
| Tanahashi, T | 1 |
| Josen, T | 1 |
| Nasu, Y | 1 |
| Evans, WK | 1 |
| Wierzbicki, R | 1 |
| Shepherd, FA | 1 |
| Rusthoven, J | 1 |
| Stewart, DJ | 1 |
| Aitken, SE | 1 |
| Maroun, JA | 1 |
| Ezzat, A | 1 |
| Nagamoto, A | 1 |
| Kubota, Y | 1 |
| Shuin, T | 1 |
| Kondo, I | 1 |
| Moriyama, M | 1 |
| Satomi, Y | 1 |
| Fukushima, S | 1 |
| Fukuoka, H | 1 |
| Ishizuka, E | 1 |
| Furuhata, A | 1 |
| Loprinzi, CL | 1 |
| Miser, AW | 1 |
| Kardinal, C | 1 |
| Everson, LK | 1 |
| Ahlquist, DA | 1 |
| Dose, AM | 1 |
| Moertel, CG | 1 |
| Jinushi, K | 1 |
| Kim, R | 1 |
| Toi, M | 1 |
| Saeki, K | 1 |
| Yoshinaka, K | 1 |
| Yanagawa, E | 1 |
| Niimoto, M | 1 |
| Hattori, T | 1 |
| Abe, O | 1 |
| Iino, Y | 1 |
| Fujimoto, M | 1 |
| Nomura, Y | 1 |
| Kitamura, M | 1 |
| Hayashi, K | 1 |
| Takahashi, I | 1 |
| Kosaki, G | 1 |
| Sawaki, S | 1 |
| Tamamushi, N | 1 |
| Takahashi, H | 1 |
| Yao, K | 1 |
| Takeyama, I | 1 |
| Otake, H | 1 |
| Miyake, H | 1 |
| Horiuchi, M | 1 |
| Hattori, Y | 1 |
| Murakami, T | 1 |
| Furue, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Open-label, Multicenter Trial of the Chemoradiation Versus Standard Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Cancer in Chinese Patients[NCT02972372] | 196 participants (Anticipated) | Interventional | 2016-11-30 | Recruiting | |||
| Two-arm Phase III Trial Comparing Radiotherapy With Differentcycles of Cisplatin-5-fluorouracil for Esophageal Cancer[NCT02607540] | Phase 3 | 210 participants (Anticipated) | Interventional | 2014-10-31 | Recruiting | ||
| Three-arm Phase III Trial Comparing Radiotherapy With Different Chemotherapy Regimens for Esophageal Cancer[NCT02025036] | Phase 3 | 249 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Phase II Study of Paclitaxel Liposome Plus S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer[NCT02163291] | Phase 2 | 30 participants (Anticipated) | Interventional | 2013-12-31 | Not yet recruiting | ||
| A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma[NCT02254681] | Phase 2 | 6 participants (Actual) | Interventional | 2014-09-30 | Terminated (stopped due to lack of funding) | ||
| Phase II Study of an All-Oral Combination of Capecitabine (X) and Cyclophosphamide (C) in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer[NCT00589901] | Phase 2 | 60 participants (Anticipated) | Interventional | 2006-08-31 | Recruiting | ||
| A Phase I/II Study of Vorinostat (Zolinza®) in Combination With Capecitabine (X) and Cisplatin (P) for 1st Line Treatment of Metastatic or Recurrent Gastric Cancer[NCT01045538] | Phase 1/Phase 2 | 45 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| A Phase ll Study of Oxaliplatin, Capecitabine, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas[NCT00447330] | Phase 2 | 60 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Randomized Open-label Trial of Dose Dense, Fixed Dose Capecitabine Compared to Standard Dose Capecitabine in Metastatic Breast Cancer and Advanced/Metastatic Gastrointestinal Cancers.[NCT02595320] | Phase 2 | 200 participants (Actual) | Interventional | 2015-10-05 | Active, not recruiting | ||
| Sorafenib Alone Versus Sorafenib Combined With Hepatic Arterial Chemoinfusion for Advanced HCC With Portal Vein Tumor Thrombosis: a Multicentre Randomised Controlled Trial[NCT02774187] | Phase 3 | 247 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma[NCT02981498] | Phase 2 | 35 participants (Anticipated) | Interventional | 2015-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the number of participants with Intrahepatic disease progression assessed by MRI of the abdomen with intravenous gadolinium contrast using RECIST criteria. (NCT02254681)
Timeframe: From date of first treatment until date of first documented progression or date of death from any cause, which ever comes first, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 6 |
To determine the number of participants with Intrahepatic recurrence assessed by RECIST criteria using MRI of the abdomen with intravenous gadolinium contrast. (NCT02254681)
Timeframe: From date of partial hepatectomy until date of first documented recurrence or date of death from any cause, assessed up to 24 months.
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Measured post-operative complications include (but not limited to) bile leak, liver failure, ascites, infection, any organ failure or insufficiency, venous thromboembolism, and mortality. (NCT02254681)
Timeframe: up to 90 days after partial hepatectomy
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment | 1 |
Time in months from the start of study treatment to the date of first progression (PD) according to the RECIST criteria, or death due to any cause. PER RECIST, a PD is indicated when there is at least a 20% increase in the sum of the longest diameters from target lesions relative to the smallest sum recorded since treatment is initiated. Median PFS was estimated using a Kaplan-Meier curve, and is the time at which 50% of patients remain alive without disease progression. (NCT00447330)
Timeframe: 5 years from study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1- Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avastin | 6.97 |
Time in months from the start of study treatment to date of death due to any cause. Median survival was estimated using a Kaplan-Meier curve and is the time point at which 50% of patients remain alive. (NCT00447330)
Timeframe: 5 years after study start date
| Intervention | survival time in months (Median) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 10.51 |
The proportion of patients for whom the best overall response is complete response (CR) or partial response (PR). A CR occurs when all lesions disappear; whereas, a PR is indicated when there is at least a 30% decrease in the sum of the longest diameters (LD) of the target lesion. A PD (progressive disese) occurs when there is at least a 20% increase in the sum of the LD relative to the smallest sum LD recorded since treatment is initiated. Disease is considered stable if there is no response and no PD. All patients were assigned a best response for inclusion in this calculation in accordance with the protocol. (NCT00447330)
Timeframe: Every 9 weeks for up to 1 year
| Intervention | percentage of participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 41.7 |
Number of subjects who experienced an adverse event (NCT00447330)
Timeframe: Every 21 days
| Intervention | participants (Number) |
|---|---|
| 1 - Capecitabine (Xeloda), Oxaliplatin and Bevacizumab (Avasti | 56 |
2 reviews available for fluorouracil and Anorexia
| Article | Year |
|---|---|
[S-1 as a single agent for colorectal cancer].
Topics: Administration, Oral; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2006 |
[Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil].
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Diarrhea; Dogs; Drug Combinations; Female; Fluor | 1998 |
42 trials available for fluorouracil and Anorexia
| Article | Year |
|---|---|
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Che | 2013 |
A multicentre randomised trial comparing weekly paclitaxel + S-1 with weekly paclitaxel + 5-fluorouracil for patients with advanced gastric cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protoc | 2013 |
Randomized Phase III study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106).
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2013 |
Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 tria
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemothera | 2013 |
Pharmacokinetics, safety, and efficacy of FOLFIRI plus bevacizumab in Japanese colorectal cancer patients with UGT1A1 gene polymorphisms.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Proto | 2014 |
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Co | 2016 |
A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Topics: Adult; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Be | 2016 |
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy | 2016 |
Phase I/II study of capecitabine plus oxaliplatin (XELOX) plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer.
Topics: Adult; Aged; Anorexia; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Com | 2010 |
Nutritional status of patients with locally advanced pancreatic cancer: a pilot study.
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Body Weight; Cachexia; Capecitabine; Combined Modal | 2011 |
Phase II study of weekly paclitaxel, cisplatin, and 5-fluorouracil for advanced gastric cancer.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin | 2011 |
Docetaxel plus gemcitabine in combination with capecitabine as treatment for inoperable pancreatic cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecit | 2012 |
An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study.
Topics: Administration, Oral; Adult; Aged; Anorexia; Anthracyclines; Antineoplastic Combined Chemotherapy Pr | 2012 |
A pilot phase II study of capecitabine in advanced or recurrent colorectal cancer.
Topics: Administration, Oral; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Colonic Neoplas | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
A phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancer.
Topics: Administration, Oral; Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Capecitabine; Deoxycyt | 2004 |
[Phase I study of concurrent radiotherapy with TS-1 and vitamin A (TAR Therapy) for head and neck cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dru | 2005 |
[Multicenter comparative study of the recurrence-inhibitory effect of oral fluoropyrimidine drugs in patients with colorectal cancer following curative resection].
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Pr | 2005 |
Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Dose-Respo | 2006 |
A phase I/II study of combination chemotherapy with gemcitabine and 5-fluorouracil for advanced pancreatic cancer.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free S | 2006 |
[A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deox | 2006 |
[A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant set
Topics: Anorexia; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Ne | 2006 |
[Combination chemotherapy with hepatic arterial infusion of 5-fluorouracil (5-FU) and systemic irinotecan (CPT-11) in patients with unresectable liver metastases from colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neop | 2006 |
[Phase I/II clinical trial of induction chemotherapy with nedaplatin (CDGP), docetaxel (DOC) and 5-fluorouracil (5-FU) for squamous cell carcinoma of head and neck].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous | 2007 |
5-Fluorouracil, methyl-CCNU, and radiotherapy with or without testolactone for localized adenocarcinoma of the exocrine pancreas: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Aged; Agranulocytosis; Anorexia; Antineoplastic Agents; Clinical Trials as Topic; Do | 1980 |
[A late phase II trial of l-leucovorin and 5-fluorouracil in advanced colorectal cancer. l-Leucovorin and 5-FU Study Group (Japan Western Group)].
Topics: Adult; Aged; Anorexia; Colorectal Neoplasms; Diarrhea; Drug Administration Schedule; Female; Fluorou | 1995 |
[Biochemically modulated chemotherapy with high-dose L-leucovorin and 5-fluorouracil for multiple liver metastasis from colorectal cancer].
Topics: Adenocarcinoma; Aged; Anorexia; Colorectal Neoplasms; Female; Fluorouracil; Humans; Leucovorin; Live | 1995 |
[Clinical effects of carmofur (Mifurol) on advanced and recurrent breast cancer in a cooperative study. Research association for re-evaluation of direct effects of Mifurol on breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Dizziness; Dru | 1995 |
[Combination chemotherapy with FP versus FEP in patients with advanced gastric cancer. Research group of gastric cancer chemotherapy].
Topics: Adenocarcinoma; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admi | 1995 |
[Sequential methotrexate/5-fluorouracil therapy with 5'-deoxy-5-fluorouridine against advanced gastric cancer: comparison between bolus injection and drip infusion of 5-fluorouracil administration. Hirosaki Cooperative Study Group for Cancer Chemotherapy]
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Ch | 1994 |
[Evaluation of chemotherapy in the treatment of advanced colorectal cancer--pilot study of 5-FU by biochemical modulation].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 1996 |
[A randomized comparative study of surgical adjuvant chemotherapy using 5-fluorouracil and dl-leucovorin with CDDP 5-FU and dl-leucovorin for colorectal cancer].
Topics: Adenocarcinoma; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Ci | 1997 |
[Evaluation of 5-fluorouracil concentration in peripheral blood and side effects in continuous hepatic arterial infusion chemotherapy for patients with unresectable liver cancer].
Topics: Abdominal Pain; Aged; Anorexia; Antimetabolites, Antineoplastic; Drug Administration Schedule; Femal | 1997 |
[A cooperative study on concomitant with low-dose divided administration of cisplatin (CDDP) and sustained drip infusion of 5-fluorouracil (5-FU) for unresectable advanced gastric cancer. Osaka Cisplatin Gastric Cancer Study Group].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administratio | 1998 |
Weekly 24 h infusion of high-dose 5-fluorouracil and leucovorin in patients with biliary tract carcinomas.
Topics: Aged; Anorexia; Antidotes; Antimetabolites, Antineoplastic; Biliary Tract Neoplasms; Bone Marrow; Di | 1998 |
Postoperative complications in patients of esophageal cancer after neoadjuvant chemotherapy.
Topics: Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Esophage | 1999 |
Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Carcinoma, Renal Cell; Chills; Combined Moda | 2001 |
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protoco | 2001 |
5-Fluorouracil with folinic acid is not effective against metastatic adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Allopurinol; Anorexia; Antineoplastic Combined Chemotherapy Protocols; | 1990 |
[Phase II study of 5-FU tablet in bladder tumor].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Carcinoma, Transitional Cell; Drug E | 1989 |
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplas | 1989 |
[A randomized controlled study of (2'' R)-4'-O-tetrahydropyranyladriamycin and adriamycin in combination with cyclophosphamide and 5-fluorouracil in the treatment of advanced and recurrent breast cancer].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxoru | 1986 |
[Preliminary report of adjuvant chemo-endocrine therapy for breast cancer].
Topics: Adult; Anorexia; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Combined Modality Therapy | 1985 |
29 other studies available for fluorouracil and Anorexia
| Article | Year |
|---|---|
FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis of data from a nationwide multicenter observational study in Japan.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Female; Fluorouracil; Glucuro | 2020 |
Gemcitabine Plus Nab-Paclitaxel Versus FOLFIRINOX in Locally Advanced, Unresectable Pancreatic Cancer: A Multicenter Observational Study (NAPOLEON Study).
Topics: Adult; Aged; Albumins; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Diar | 2021 |
Z-505 hydrochloride ameliorates chemotherapy-induced anorexia in rodents via activation of the ghrelin receptor, GHSR1a.
Topics: Amides; Animals; Anorexia; Antineoplastic Agents; Body Weight; CHO Cells; Cisplatin; Cricetinae; Cri | 2018 |
Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil.
Topics: Adult; Aged; Anorexia; Antimetabolites, Antineoplastic; Anxiety; Carcinoma; Chemoradiotherapy; Cispl | 2013 |
Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Biliary Tract Neoplasms; Capecitabi | 2013 |
Intraarterial chemotherapy as the first-line therapy in penile cancer.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; | 2014 |
Growth hormone releasing peptide 2 reverses anorexia associated with chemotherapy with 5-fluoruracil in colon cancer cell-bearing mice.
Topics: Animals; Anorexia; Antimetabolites, Antineoplastic; Appetite Stimulants; Body Weight; Cachexia; Cell | 2008 |
Steroids, cancer and vertebral fractures: a dreaded combination.
Topics: Adrenal Cortex Hormones; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabin | 2011 |
Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
Topics: Adult; Aged; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous C | 2011 |
Intensity-modulated radiation therapy with concurrent chemotherapy as preoperative treatment for localized gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; | 2012 |
[The prevention of negative side effects in homeochemotherapy].
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neop | 2002 |
[Cisplatin, 5-fluorouracil, and high-dose leucovorin for advanced esophageal cancer].
Topics: Aged; Aged, 80 and over; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2003 |
[Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer].
Topics: Aged; Anorexia; Antimetabolites, Antineoplastic; Colorectal Neoplasms; Drug Administration Schedule; | 2003 |
[Second-line chemotherapy with bi-weekly CPT-11 and cisplatin for recurrent colorectal cancer resistant to 5-FU based chemotherapy].
Topics: Adult; Aged; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cispl | 2005 |
[Clinical administration of oxaliplatin for patients previously treated for refractory advanced or recurrent colorectal cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administr | 2006 |
[Interferon-alpha+cisplatin+5-FU therapy for gemcitabine-refractory unresectable and recurrent pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Admin | 2006 |
[Evaluation of weekly low-dose CPT-11 combined with 5-FU/l-LV therapy for advanced and recurrent colorectal cancer--preliminary study].
Topics: Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Col | 2006 |
The anti-cancer drug-induced pica in rats is related to their clinical emetogenic potential.
Topics: Animals; Anorexia; Antineoplastic Agents; Cisplatin; Dactinomycin; Fluorouracil; Kaolin; Male; Pica; | 2007 |
[Feasibility of modified FOLFIRI regimen for patients with refractory advanced or recurrent colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neoplas | 2007 |
[Clinical administration of FOLFOX regimens for patients with unresectable advanced or recurrent colorectal cancer].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; C | 2007 |
[The first report from Sapporo Tsukisamu Hospital--chemotherapy and chemoradiotherapy for patients with advanced pancreatic cancer].
Topics: Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy | 2007 |
[The second report from Sapporo Tsukisamu hospital--chemotherapy for patients with advanced colorectal cancer].
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Colorectal Neoplas | 2007 |
Combination chemotherapy for advanced bladder cancer with adriamycin, cyclophosphamide, and 5-fluorouracil.
Topics: Actuarial Analysis; Adenocarcinoma; Alopecia; Anorexia; Antineoplastic Combined Chemotherapy Protoco | 1983 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
A novel chemotherapy for advanced hepatocellular carcinoma with tumor thrombosis of the main trunk of the portal vein.
Topics: Aged; alpha-Fetoproteins; Anorexia; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineop | 1997 |
Squamous cell carcinoma of the pancreas with cystic degeneration.
Topics: Abdominal Pain; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Squamou | 2000 |
[Phase II study of 5'-DFUR treatment of the bladder and prostatic cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Diarrhea; Dru | 1991 |
[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].
Topics: Anorexia; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Administration Sche | 1989 |
[Chemotherapy with FT-207 suppository (Futraful Supo) in head and neck cancer--cooperative studies by six medical schools in Kanagawa Prefecture].
Topics: Adult; Aged; Anorexia; Carcinoma, Squamous Cell; Drug Administration Schedule; Female; Fluorouracil; | 1985 |
[590-S].
Topics: Administration, Oral; Adult; Animals; Anorexia; Antineoplastic Agents; Drug Administration Schedule; | 1985 |